Kurt B. McMaken
Known title: DirectorCIK: 0001455831
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Brink's Gets CMA Approval for NCR Atleos Deal Remedy. Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.
Transaction History
| DD | ▲ Buy | Grant | 4,030 | $0 | 5/21/2026 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 699 | $88K | 3/3/2026 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 742 | $93K | 3/3/2026 | View on chart |
| BCO | ▲ Buy | Grant | 4,035 | $0 | 3/2/2026 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 774 | $90K | 3/1/2026 | View on chart |
| BCO | ▲ Buy | Grant | 30,308 | $3.9M | 2/18/2026 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 13,028 | $1.7M | 2/18/2026 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 651 | $76K | 9/30/2025 | View on chart |
| DD | ▲ Buy | Grant | 2,794 | $0 | 5/22/2025 | View on chart |
| DD | ▲ Buy | Grant | 1,368 | $0 | 3/18/2025 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 586 | $52K | 3/3/2025 | View on chart |
| BCO | ▲ Buy | Grant | 5,192 | $0 | 3/3/2025 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 648 | $61K | 3/1/2025 | View on chart |
| BCO | ▲ Buy | Grant | 40,956 | $0 | 2/19/2025 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 14,735 | $1.4M | 2/19/2025 | View on chart |
| BCO | ▲ Buy | Grant | 5,780 | $0 | 2/19/2025 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 2,073 | $196K | 2/19/2025 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 3,174 | $367K | 9/30/2024 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 625 | $52K | 3/3/2024 | View on chart |
| BCO | ▲ Buy | Grant | 5,416 | $0 | 3/1/2024 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 3,794 | $276K | 9/30/2023 | View on chart |
| BCO | ▲ Buy | Grant | 4,895 | $0 | 3/3/2023 | View on chart |
| BCO | ▲ Buy | Grant | 5,447 | $300K | 8/24/2022 | View on chart |
| BCO | ▲ Buy | Grant | 14,724 | $800K | 8/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DuPont receives analyst upgrades and announces quarterly dividend
DuPont de Nemours was highlighted in several recent analyst reports. RBC Capital kept an Outperform rating while lowering its price target to $160, and Barclays began coverage with an Overweight rating and a $156 target. The company also announced its regular quarterly dividend for common stock. These developments show ongoing analyst attention and a focus on returning cash to shareholders.
DuPont receives analyst upgrades and announces quarterly dividend. DuPont de Nemours was highlighted in several recent analyst reports. RBC Capital kept an Outperform rating while lowering its price target to $160, and Barclays began coverage with an Overweight rating and a $156 target. The company also announced its regular quarterly dividend for common stock. These developments show ongoing analyst attention and a focus on returning cash to shareholders.